Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUCL 2077
Discontinued Product
UCL 2077 (Cat. No. 2661) has been withdrawn from sale for commercial reasons.
Description: Slow afterhyperpolarization (sAHP) channel blocker; sub-type selective Kv channel effects
Chemical Name: N-Trityl-3-pyridinemethanamine
Purity: ≥99% (HPLC)
Biological Activity for UCL 2077
UCL 2077 is a slow afterhyperpolarization (sAHP) channel blocker; reduces sAHP in hippocampal slice preparations. Displays no effect on Ca2+ currents or the time course of sAHP/sIAHP. Exhibits potent inhibition of KCNQ1 and KCNQ2, but differential effects at other KCNQs. Rescues memory retrieval in dopamine β-hydroxylase knockout mice.
Technical Data for UCL 2077
| M. Wt | 350.46 |
| Formula | C25H22N2 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 918311-87-2 |
| PubChem ID | 24868317 |
| InChI Key | PQFNWDHABGBCHB-UHFFFAOYSA-N |
| Smiles | C(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CN=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for UCL 2077
References for UCL 2077
References are publications that support the biological activity of the product.
Shah et al (2006) Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077). Mol.Pharmacol. 70 1494 PMID: 16877678
Zhang et al (2013) The slow afterhyperpolarization: a target of β1-adrenergic signaling in hippocampus-dependent memory retrieval. J.Neurosci. 33 5006 PMID: 23486971
Soh and Tzingounis (2010) The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol.Pharmacol. 78 1088 PMID: 20843955
View Related Products by Target
View Related Products by Product Action
Keywords: UCL 2077, UCL 2077 supplier, Slow, hyperpolarization, sAHP, channels, blockers, Potassium, KCa, Channels, ca2+-activated, ca2+-dependent, K+, UCL2077, Ca2+-Activated, Voltage-Gated, 2661, Tocris Bioscience
2 Citations for UCL 2077
Citations are publications that use Tocris products. Selected citations for UCL 2077 include:
Paz et al (2018) Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac. Neuropharmacology 137 309 PMID: 29758221
Zhang et al (2013) The slow afterhyperpolarization: a target of β1-adrenergic signaling in hippocampus-dependent memory retrieval. J Neurosci 33 5006 PMID: 23486971
Reviews for UCL 2077
Average Rating: 5 (Based on 1 Review.)
Have you used UCL 2077?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
UCL 2077 in BK channel study.
By
Anonymous on 12/03/2018
Assay Type: In Vitro
Species: Human
UCL 2077 has been used in our lab for assessing its blocking capacity in BK channels. the results were reliable and reproducible. Great product and will purchase again.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.